Max Delbruck Center for Molecular Medicine:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Max Delbruck Center for Molecular Medicine - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12383
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Max Delbruck Center for Molecular Medicine (MDC) is a biomedical research center that offers translating discoveries from molecular research into applications. The company’s research area services offer for cancer research, cardiovascular and metabolic disease, diseases of the nervous system, medical systems biology and clinical research. Its labs and fellows include research labs and fellows. MDC research labs offer biochemistry and proteomics, cancer, cardiovascular research, cell biology, computational biology, developmental biology, epidemiology and gene engineering. The company’s scientific infrastructure offers technology platforms, technology transfer, support services and animal facilities. MDC is headquartered in Berlin, Germany.

Max Delbruck Center for Molecular Medicine – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 11
Licensing Agreements 13
Fate Therapeutics Enters into Option and Licensing Agreement with Max Delbruck Center 13
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 14
Formula Pharma Enters into Licensing Agreement with Max Delbruck Center for Molecular Medicine 15
Berlin Cures Enters into Licensing Agreement with Charite and Max Delbruck Center 16
Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 17
Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 18
Max Delbruck Center for Molecular Medicine – Key Competitors 19
Max Delbruck Center for Molecular Medicine – Key Employees 20
Max Delbruck Center for Molecular Medicine – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Government and Public Interest 22
Dec 13, 2017: Molecular Chaperones Shown to Assist in the Fight against Huntington Disease 22
Product News 24
Jul 25, 2017: BeLOVE launches: first patients recruited for large study in Germany’s capital city of Berlin 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Key Facts 2
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Max Delbruck Center for Molecular Medicine, Deals By Therapy Area, 2012 to YTD 2018 8
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 11
Fate Therapeutics Enters into Option and Licensing Agreement with Max Delbruck Center 13
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 14
Formula Pharma Enters into Licensing Agreement with Max Delbruck Center for Molecular Medicine 15
Berlin Cures Enters into Licensing Agreement with Charite and Max Delbruck Center 16
Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 17
Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 18
Max Delbruck Center for Molecular Medicine, Key Competitors 19
Max Delbruck Center for Molecular Medicine, Key Employees 20

List of Figures
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Max Delbruck Center for Molecular Medicine, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Max Delbruck Center for Molecular Medicine:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Guy’s and St Thomas’ NHS Foundation Trust:企業の戦略的SWOT分析
    Guy's and St Thomas' NHS Foundation Trust - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Adient Plc (ADNT):企業の財務・戦略的SWOT分析
    Adient Plc (ADNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Dexcel PT Israel Ltd:企業の戦略的SWOT分析
    Dexcel PT Israel Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Arcam AB:企業の戦略的SWOT分析
    Arcam AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Latecoere S.A.:企業の戦略・SWOT・財務情報
    Latecoere S.A. - Strategy, SWOT and Corporate Finance Report Summary Latecoere S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • EyeGate Pharmaceuticals Inc (EYEG)-製薬・医療分野:企業M&A・提携分析
    Summary EyeGate Pharmaceuticals Inc (EyeGate) is a clinical-stage specialty pharmaceutical company that offers eye care medicines. The company offers macular edema and non-infectious anterior uveitis. It offers technologies for most prevalent issues in ophthalmic care; the existing lack of patient a …
  • Valeura Energy Inc (VLE):石油・ガス:M&Aディール及び事業提携情報
    Summary Valeura Energy Inc (Valeura) is an upstream oil and gas company that explores for, develops and produces oil and natural gas. It operates mainly in the Thrace Basin in the northwest of Turkey pursuing conventional shallow natural gas, unconventional tight gas and a basin-centered gas accumul …
  • Swagelok Company:企業の戦略・SWOT・財務情報
    Swagelok Company - Strategy, SWOT and Corporate Finance Report Summary Swagelok Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Shri Lakshmi Defence Solutions Ltd.:企業の戦略・SWOT・財務情報
    Shri Lakshmi Defence Solutions Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shri Lakshmi Defence Solutions Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • The Whiting-Turner Contracting Co:企業の戦略・SWOT・財務情報
    The Whiting-Turner Contracting Co - Strategy, SWOT and Corporate Finance Report Summary The Whiting-Turner Contracting Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • U-Haul International, Inc.:企業の戦略的SWOT分析
    U-Haul International, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • TG Therapeutics Inc (TGTX):企業の財務・戦略的SWOT分析
    TG Therapeutics Inc (TGTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Heidelberger Druckmaschinen AG (HDD):企業の財務・戦略的SWOT分析
    Heidelberger Druckmaschinen AG (HDD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Terna Energy SA (TENERGY)-エネルギー分野:企業M&A・提携分析
    Summary Terna Energy SA (Terna Energy) a member of the GEK Terna Group, is an independent power producer. It has a presence in the renewable energy project vertical, from site investigation and assessment of available renewable energy potential, to the design, licensing, construction, and the operat …
  • Pure Technologies Ltd:企業の戦略的SWOT分析
    Pure Technologies Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Finnair Oyj:企業のM&A・事業提携・投資動向
    Finnair Oyj - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Finnair Oyj Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Metropolitan Bank and Trust Company:企業の戦略・SWOT・財務分析
    Metropolitan Bank and Trust Company - Strategy, SWOT and Corporate Finance Report Summary Metropolitan Bank and Trust Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Relmada Therapeutics Inc (RLMDD):企業の財務・戦略的SWOT分析
    Summary Relmada Therapeutics Inc (Relmada Therapeutics), formerly Camp Nine Inc, is a pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s product pipeline includes REL-1017 d-Methadone, an antagonist for the treat …
  • Vitasoy International Holdings Limited (345):企業の財務・戦略的SWOT分析
    Vitasoy International Holdings Limited (345) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • China State Shipbuilding Corp:企業の戦略・SWOT・財務情報
    China State Shipbuilding Corp - Strategy, SWOT and Corporate Finance Report Summary China State Shipbuilding Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆